HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two abstracts submitted by the Company’s collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa have been accepted for presentation at the Hemophilia 2008 World Congress, the XXVIIIth International Congress of the World Federation of Hemophilia taking place in Istanbul, Turkey at the Lütfi Kirdar Convention & Exhibition Centre from June 1-5, 2008.
